Bladder Cancer New Reference: Neoadjuvant CISplatin and Gemcitabine for Urothelial Cancer Ulas D. Bayraktar, MD 2023-03-15
Breast Cancer New Indication: Sacituzumab Govitecan for HR+, her2 Negative Breast Cancer Ulas D. Bayraktar, MD 2023-03-15
Colorectal Cancer New Indication: Encorafenib, Binimetinib, and Cetuximab for bRAF V600E Mutant Colorectal Cancer Ulas D. Bayraktar, MD 2023-03-15
Waldenstrom macroglobulinemia New Reference: Bortezomib, Rituximab, Cyclophosphamide for Waldenstrom Ulas D. Bayraktar, MD 2023-03-15
Mantle cell lymphoma New Drug: Pirtobrutinib in Mantle Cell Lymphoma Ulas D. Bayraktar, MD 2023-03-15
Colorectal Cancer New Drug: Adagrasib with/without Cetuximab in kRAS G12C Mutant Colorectal Cancer Ulas D. Bayraktar, MD 2023-03-15
Head and Neck Cancer New Indicaiton: DOCEtaxel as a Radiosensitizer in Head and Neck Cancer Ulas D. Bayraktar, MD 2023-03-15
